search for




 

An Analysis on Prescribing Patterns of Alzheimer’s Dementia Treatment and Choline Alfoscerate using HIRA Claims Data
Korean J Clin Pharm 2019;29(1):1-8
Published online March 31, 2019
© 2019 Korean College of Clinical Pharmacy.

Sang Goo Hwang and Hyekyung Park*

College of Pharmacy, Sungkyunkwan University, Gyeong gi-do 16419, Republic of Korea
Correspondence to: Hyekyung Park, College of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon-si, Gyeong gi-do 16419, Republic of Korea
Tel: +82-31-290-7763, Fax: +82-31-292-8800, E-mail: phk94@skku.edu
Received September 27, 2018; Revised March 14, 2019; Accepted March 18, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Alzheimer's dementia is the most common dementia. However, recently, choline alfoscerate is prescribed for treating Alzheimer's dementia, although it is not a treatment for this disease. Purpose: To analyze the prescription patterns of choline alfoscerate as a dementia treatment for patients with Alzheimer's disease and to analyze, as well as the factors affecting choline alfoscerate prescription. Method: The 2016 HIRA-NPS data was used in this study. The code of Alzheimer's dementia is F00 in the ICD-10 disease classification code. We analyzed the demographic, clinical, and regional characteristics associated with donepezil, rivastigmine, galantamine, memantine, and choline alfoscerate prescriptions. All statistical and data analyse were conducted by SAS 9.4 and Excel. Results: For patients with Alzheimer's disease, choline alfoscerate was the second most prescribed after donepezil. Analysis results showed that choline alfoscerate was more likely to be prescribed to men than to women, and more likely to be prescribed by local health centers than by medical institutions. Moreover, choline alfoscerate was highly likely to be prescribed at neurosurgical departments, among medical departments. Conclusions: This study confirmed that choline alfoscerate was prescribed considerably for patients with Alzheimer's dementia. Further studies valuating its clinical validity should be performed to clarify whether choline alfoscerate prescription is appropriate for treating Alzheimer's dementia.
Keywords : Choline alfoscerate, Alzheimer's dementia, prescribing patterns, National Patient Sample data


March 2019, 29 (1)
Full Text(PDF) Free

Social Network Service
Services

Cited By Articles
  • CrossRef (0)